{"links": [{"source": 0, "target": "t24", "value": "None"}, {"source": 0, "target": "t19", "value": "None"}, {"source": 0, "target": "t7", "value": "None"}, {"source": 0, "target": "t14", "value": "None"}, {"source": "t24", "target": "t27", "value": "None"}, {"source": "t24", "target": "t25", "value": "None"}, {"source": "t24", "target": "t26", "value": "None"}, {"source": "t19", "target": "t20", "value": "None"}, {"source": "t7", "target": "t13", "value": "None"}, {"source": "t7", "target": "t12", "value": "None"}, {"source": "t7", "target": "t8", "value": "None"}, {"source": "t14", "target": "t15", "value": "None"}, {"source": "t25", "target": "t28", "value": "None"}, {"source": "t26", "target": "t28", "value": "None"}, {"source": "t20", "target": "t21", "value": "None"}, {"source": "t12", "target": "t1", "value": "None"}, {"source": "t8", "target": "t9", "value": "None"}, {"source": "t15", "target": "t16", "value": "None"}, {"source": "t21", "target": "t22", "value": "None"}, {"source": "t1", "target": "t2", "value": "None"}, {"source": "t9", "target": "t10", "value": "None"}, {"source": "t16", "target": "t17", "value": "None"}, {"source": "t22", "target": "t23", "value": "None"}, {"source": "t2", "target": "t3", "value": "None"}, {"source": "t10", "target": "t11", "value": "None"}, {"source": "t17", "target": "t18", "value": "None"}, {"source": "t3", "target": "t4", "value": "None"}, {"source": "t4", "target": "t5", "value": "None"}, {"source": "t5", "target": "t6", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Allergies", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Allergies"}}, {"category": "treatment", "id": "t24", "name": "person under 19 with possible food allergy", "draggable": "true", "value": {"name": "person under 19 with possible food allergy", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person under 19 with possible food allergy", "drug": {}}}, {"category": "treatment", "id": "t19", "name": "person with a drug allergy", "draggable": "true", "value": {"name": "person with a drug allergy", "type": "treatment related", "time": "", "intention": "", "description": "title:person with a drug allergy", "drug": {}}}, {"category": "treatment", "id": "t7", "name": "drug allergy", "draggable": "true", "value": {"name": "drug allergy", "type": "treatment related", "time": "", "intention": "", "description": "title:drug allergy", "drug": {}}}, {"category": "treatment", "id": "t14", "name": "person under 19 with possible food allergy in primary care or community setting", "draggable": "true", "value": {"name": "person under 19 with possible food allergy in primary care or community setting", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person under 19 with possible food allergy in primary care or community setting", "drug": {}}}, {"category": "treatment", "id": "t27", "name": "diagnostic tools not recommended", "draggable": "true", "value": {"name": "diagnostic tools not recommended", "type": "treatment related", "time": "", "intention": "", "description": "title:diagnostic tools not recommendedhead:Diagnostic tools not recommendedDo not use the following alternative diagnostic tests in the diagnosis of food allergy: vega test applied kinesiology hair analysis.Do not use serum-specific IgG testing to diagnose food allergy.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG116", "drug": {}}}, {"category": "treatment", "id": "t25", "name": "suspected ige mediated food allergy", "draggable": "true", "value": {"name": "suspected ige mediated food allergy", "type": "treatment related", "time": "", "intention": "", "description": "title:suspected ige-mediated food allergyhead:Suspected IgE-mediated food allergysubhead:Skin prick test and/or blood tests for specific IgE antibodiesBased on the results of the allergy-focused clinical history, if IgE-mediated allergy is suspected, offer the child or young person a skin prick test and/or blood tests for specific IgE antibodies to the suspected foods and likely co-allergens.Tests should only be undertaken by healthcare professionals with the appropriate competencies to select, perform and interpret them.Skin prick tests should only be undertaken where there are facilities to deal with an anaphylactic reaction.Choose between a skin prick test and a specific IgE antibody blood test based on: the results of the allergy-focused clinical history and whether the test is suitable for, safe for and acceptable to the child or young person (or their parent or carer) and the available competencies of the healthcare professional to undertake the test and interpret the results.Do not carry out allergy testing without first taking an allergy-focused clinical history. Interpret the results of tests in the context of information from the allergy-focused clinical history.Do not use atopy patch testing or oral food challenges to diagnose IgE-mediated food allergy in primary care or community settings.subhead:Multiplex allergen testingThe following recommendations are from NICE diagnostics guidance on ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing.There is currently insufficient evidence to recommend the routine adoption of multiplex allergen testing, ImmunoCAP ISAC\u00a0112 or Microtest, to help diagnose allergy and predict the risk of an allergic reaction in people with allergy that is difficult to diagnose, when used with standard clinical assessment. The ImmunoCAP ISAC\u00a0112 shows promise and further research is recommended on the clinical effectiveness of using it in people with allergy that is difficult to diagnose (see recommendations for further research). Microtest is a new technology and further research by the company to show its clinical effectiveness is encouraged.An allergy healthcare professional with appropriate expertise is needed to ensure the results of multiplex allergen tests are interpreted correctly.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Food allergy quality standard2Diagnosing IgE-mediated food allergySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG116DG24", "drug": {}}}, {"category": "treatment", "id": "t26", "name": "suspected non ige mediated food allergy", "draggable": "true", "value": {"name": "suspected non ige mediated food allergy", "type": "information and support", "time": "", "intention": "", "description": "title:suspected non-ige-mediated food allergyhead:Suspected non-IgE-mediated food allergyBased on the results of the allergy-focused clinical history, if non-IgE-mediated food allergy is suspected, trial elimination of the suspected allergen (normally for between 2-6 weeks) and reintroduce after the trial. Seek advice from a dietitian with appropriate competencies, about nutritional adequacies, timings of elimination and reintroduction, and follow-up.If a food elimination diet is advised as part of the diagnostic process, offer the child or young person and their parent or carer, taking into account socioeconomic status and cultural and religious issues, information on:  what foods and drinks to avoid how to interpret food labels alternative sources of nutrition to ensure adequate nutritional intake the safety and limitations of an elimination diet the proposed duration of the elimination diet when, where and how an oral food challenge or food reintroduction procedure may be undertaken the safety and limitations of the oral food challenge or food reintroduction procedure.subhead:Cow s milk protein allergyNICE has published a clinical knowledge summary on cow s milk protein allergy in children. This practical resource is for primary care professionals (it is not formal NICE guidance).Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Food allergy quality standard3Diagnosing non-IgE-mediated food allergySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG116", "drug": {}}}, {"category": "treatment", "id": "t20", "name": "non specialist management", "draggable": "true", "value": {"name": "non specialist management", "type": "information and support", "time": "", "intention": "", "description": "title:non-specialist managementhead:Non-specialist managementIf drug allergy is suspected: consider stopping the drug suspected to have caused the allergic reaction and advising the person to avoid that drug in future treat the symptoms of the acute reaction if needed; send people with severe reactions to hospital document details of the suspected drug allergy in the person s medical records (see documenting new suspected drug allergic reactions and the recommendation on checking a person s drug allergy status in maintaining and sharing drug allergy information) provide the person with information (see information and support).subhead:Non-steroidal anti-inflammatory drugs (including selective cyclooxygenase 2 inhibitors)For people who have had a mild allergic reaction to a non-selective NSAID but need an anti-inflammatory: discuss the benefits and risks of selective COX-2 inhibitors (including the low risk of drug allergy)  consider introducing a selective COX-2 inhibitor at the lowest starting dose with only a single dose on the first day.Do not offer a selective COX-2 inhibitor to people in a non-specialist setting if they have had a severe reaction, such as anaphylaxis, severe angioedema or an asthmatic reaction, to a non-selective NSAID.Be aware that people with asthma who also have nasal polyps are likely to have NSAID-sensitive asthma unless they are known to have tolerated NSAIDs in the last 12 months.For other recommendations on allergy to NSAIDs see information and support and when to refer to a specialist drug allergy service.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t13", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t12", "name": "anaphylaxis", "draggable": "true", "value": {"name": "anaphylaxis", "type": "treatment related", "time": "", "intention": "", "description": "title:anaphylaxis", "drug": {}}}, {"category": "treatment", "id": "t8", "name": "assessment", "draggable": "true", "value": {"name": "assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:assessmenthead:AssessmentWhen assessing a person presenting with possible drug allergy, take a history and undertake a clinical examination. Use signs and allergic patterns of suspected drug allergy with timing of onset as a guide when deciding whether to suspect drug allergy. Be aware that the reaction is more likely to be caused by drug allergy if it occurred during or after use of the drug and: the drug is known to cause that type of reaction or the person has previously had a similar reaction to that drug or drug class.Be aware that the reaction is less likely to be caused by drug allergy if: there is a possible non-drug cause for the person s symptoms (for example, they have had similar symptoms when not taking the drug) or the person has gastrointestinal symptoms only. See what NICE says on on gastrointestinal conditions.subhead:Measuring serum tryptase after suspected anaphylaxisAfter a suspected drug-related anaphylactic reaction, take 2 blood samples for mast cell tryptase in line with NICE s recommendations on anaphylaxis.Record the exact timing of both blood samples taken for mast cell tryptase: in the person s medical records and on the pathology request form.Ensure that tryptase sampling tubes are included in emergency anaphylaxis kits.subhead:Measuring serum specific immunoglobulin EDo not use blood testing for serum specific IgE to diagnose drug allergy in a non-specialist setting.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Documentation using the structured assessment guideSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t15", "name": "initial recognition", "draggable": "true", "value": {"name": "initial recognition", "type": "treatment related", "time": "", "intention": "", "description": "title:initial recognitionhead:Initial recognitionConsider the possibility of food allergy in children and young people who have one or more of the signs and symptoms of possible food allergy. Pay particular attention to persistent symptoms that involve different organ systems.Consider the possibility of food allergy in children and young people whose symptoms do not respond adequately to treatment for: atopic eczema (see treating atopic eczema in children aged 12 and under in NICE s recommendations on eczema for further details) gastro-oesophageal reflux disease (see NICE s recommendations on dyspepsia and gastro-oesophageal reflux disease for further details) chronic gastrointestinal symptoms, including chronic constipation (see NICE s recommendations on constipation for further details).See also NICE s recommendations on faltering growth.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Atopic eczema in under 12s quality standard6Specialist allergy investigationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG116", "drug": {}}}, {"category": "treatment", "id": "t28", "name": "consider referral to secondary or specialist care", "draggable": "true", "value": {"name": "consider referral to secondary or specialist care", "type": "treatment related", "time": "", "intention": "", "description": "title:consider referral to secondary or specialist carehead:Consider referral to secondary or specialist careBased on the allergy-focused clinical history, consider referral to secondary or specialist care in any of the following circumstances. The child or young person has: faltering growth in combination with one or more of the gastrointestinal symptoms described in signs and symptoms of possible food allergy not responded to a single-allergen elimination diet had one or more acute systemic reactions had one or more severe delayed reactions confirmed IgE-mediated food allergy and concurrent asthma significant atopic eczema where multiple or cross-reactive food allergies are suspected by the parent or carer. There is: persisting parental suspicion of food allergy (especially in children or young people with difficult or perplexing symptoms) despite a lack of supporting history strong clinical suspicion of IgE-mediated food allergy but allergy test results are negative clinical suspicion of multiple food allergies.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Food allergy quality standard4Referral to secondary or specialist careSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG116", "drug": {}}}, {"category": "treatment", "id": "t21", "name": "when to refer to a specialist drug allergy service", "draggable": "true", "value": {"name": "when to refer to a specialist drug allergy service", "type": "treatment related", "time": "", "intention": "", "description": "title:when to refer to a specialist drug allergy servicehead:When to refer to a specialist drug allergy serviceRefer people to a specialist drug allergy service if they have had: a suspected anaphylactic reaction (also see NICE s recommendations on anaphylaxis) or a severe non-immediate cutaneous reaction (for example, DRESS, Stevens\u2013Johnson Syndrome, toxic epidermal necrolysis).subhead:Non-steroidal anti-inflammatory drugs (including selective cyclooxygenase 2 inhibitors)Refer people who need treatment with an NSAID to a specialist drug allergy service if they have had a suspected allergic reaction to an NSAID with symptoms such as anaphylaxis, severe angioedema or an asthmatic reaction.  For other recommendations on allergy to NSAIDs see information and support and non-specialist management.subhead:Beta-lactam antibioticsRefer people with a suspected allergy to beta-lactam antibiotics to a specialist drug allergy service if they: need treatment for a disease or condition that can only be treated by a beta-lactam antibiotic or are likely to need beta-lactam antibiotics frequently in the future (for example, people with recurrent bacterial infections or immune deficiency).Consider referring people to a specialist drug allergy service if they are not able to take beta-lactam antibiotics and at least 1 other class of antibiotic because of suspected allergy to these antibiotics.subhead:Local anaestheticsRefer people to a specialist drug allergy service if they need a procedure involving a local anaesthetic that they are unable to have because of suspected allergy to local anaesthetics.subhead:General anaesthesiaRefer people to a specialist drug allergy service if they have had anaphylaxis or another suspected allergic reaction during or immediately after general anaesthesia.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.3Referral to specialist drug allergy servicesSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t1", "name": "documenting drug allergy", "draggable": "true", "value": {"name": "documenting drug allergy", "type": "treatment related", "time": "", "intention": "", "description": "title:documenting drug allergy", "drug": {}}}, {"category": "treatment", "id": "t9", "name": "documenting drug allergy and sharing information with other healthcare professionals", "draggable": "true", "value": {"name": "documenting drug allergy and sharing information with other healthcare professionals", "type": "treatment related", "time": "", "intention": "", "description": "title:documenting drug allergy and sharing information with other healthcare professionals", "drug": {}}}, {"category": "treatment", "id": "t16", "name": "allergy focused clinical history and physical examination", "draggable": "true", "value": {"name": "allergy focused clinical history and physical examination", "type": "information and support", "time": "", "intention": "", "description": "title:allergy-focused clinical history and physical examinationhead:Allergy-focused clinical history and physical examinationIf food allergy is suspected (by a healthcare professional or the parent, carer, child or young person), a healthcare professional with the appropriate competencies (either a GP or other healthcare professional) should take an allergy-focused clinical history tailored to the presenting symptoms and age of the child or young person. This should include: any personal history of atopic disease (asthma, eczema or allergic rhinitis) any individual and family history of atopic disease (such as asthma, eczema or allergic rhinitis) or food allergy in parents or siblings details of any foods that are avoided and the reasons why an assessment of presenting symptoms and other symptoms that may be associated with food allergy (see signs and symptoms of possible food allergy), including questions about: the age of the child or young person when symptoms first started speed of onset of symptoms following food contact duration of symptoms severity of reaction frequency of occurrence setting of reaction (for example, at school or home) reproducibility of symptoms on repeated exposure what food and how much exposure to it causes a reaction cultural and religious factors that affect the foods they eat who has raised the concern and suspects the food allergy what the suspected allergen is the child or young person s feeding history, including the age at which they were weaned and whether they were breastfed or formula-fed \u2013 if the child is currently being breastfed, consider the mother s diet details of any previous treatment, including medication, for the presenting symptoms and the response to this any response to the elimination and reintroduction of foods.Based on the findings of the allergy-focused clinical history, physically examine the child or young person, paying particular attention to: growth and physical signs of malnutrition signs indicating allergy-related comorbidities (atopic eczema, asthma and allergic rhinitis).Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.Food allergy quality standard1Allergy-focused clinical historySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG116", "drug": {}}}, {"category": "treatment", "id": "t22", "name": "documenting information after specialist drug allergy investigations", "draggable": "true", "value": {"name": "documenting information after specialist drug allergy investigations", "type": "treatment related", "time": "", "intention": "", "description": "title:documenting information after specialist drug allergy investigationshead:Documenting information after specialist drug allergy investigationsAfter specialist drug allergy investigations, allergy specialists should document: the diagnosis, drug name and whether the person had an allergic or non-allergic reaction the investigations used to confirm or exclude the diagnosis drugs or drug classes to avoid in future.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t2", "name": "recording drug allergy status", "draggable": "true", "value": {"name": "recording drug allergy status", "type": "treatment related", "time": "", "intention": "", "description": "title:recording drug allergy statushead:Recording drug allergy statusDocument people s drug allergy status in their medical records using 1 of the following:  drug allergy    none known   unable to ascertain  (document it as soon as the information is available). If drug allergy status has been documented, record all of the following at a minimum:  the drug name the signs, symptoms and severity of the reaction (see assessment) the date when the reaction occurred.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.4Recording drug allergy status in electronic medical recordsSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t10", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "treatment related", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportDiscuss the person s suspected drug allergy with them (and their family members or carers as appropriate) and provide structured written information (see documenting new suspected drug allergic reactions). Record who provided the information and when.Provide information in line with NICE s recommendations on patient experience.Ensure that the person (and their family members or carers as appropriate) is aware of the drugs or drug classes that they need to avoid, and advise them to check with a pharmacist before taking any over-the-counter preparations.Advise people (and their family members or carers as appropriate) to carry information they are given about their drug allergy at all times and to share this whenever they visit a healthcare professional or are prescribed, dispensed or are about to be administered a drug.Explain to people with a suspected allergy to a non-selective NSAID (and their family members or carers as appropriate) that in future they need to avoid all non-selective NSAIDs, including over-the-counter preparations. For other recommendations on allergy to NSAIDs see non-specialist management and when to refer to a specialist drug allergy service.For recommendations on providing information after specialist drug allergy investigations see providing information to people who have had specialist drug allergy investigations.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.2Advice about carrying personal structured drug informationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t17", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportBased on the allergy-focused clinical history, offer the child or young person and their parent or carer, information that is age-appropriate about the: type of allergy suspected risk of severe allergic reaction potential impact of the suspected allergy on other healthcare issues, including vaccination diagnostic process, which may include: an elimination diet followed by a possible planned rechallenge or initial food reintroduction procedure (see suspected non-IgE-mediated food allergy) skin prick tests and specific IgE antibody testing, including the safety and limitations of these tests  (see suspected IgE-mediated food allergy) referral to secondary or specialist care.Offer the child or young person and their parent or carer, information that is relevant to the type of allergy (IgE-mediated, non-IgE-mediated or mixed).For babies and young children with suspected allergy to cows  milk protein, offer: food avoidance advice to breastfeeding mothers information on the most appropriate hypoallergenic formula or milk substitute to mothers of formula-fed babies.Seek advice from a dietitian with appropriate competencies.Offer the child or young person, or their parent or carer, information about the support available and details of how to contact support groups.NICE has written information for the public on food allergy in under 19s: assessment and diagnosis.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG116", "drug": {}}}, {"category": "treatment", "id": "t23", "name": "providing information to people who have had specialist drug allergy investigations", "draggable": "true", "value": {"name": "providing information to people who have had specialist drug allergy investigations", "type": "treatment related", "time": "", "intention": "", "description": "title:providing information to people who have had specialist drug allergy investigationshead:Providing information to people who have had specialist drug allergy investigationsAllergy specialists should give the following written information to people who have undergone specialist drug allergy investigation: the diagnosis \u2013 whether they had an allergic or non-allergic reaction the drug name and a description of their reaction (see assessment) the investigations used to confirm or exclude the diagnosis drugs or drug classes to avoid in future any safe alternative drugs that may be used.Explain to people in whom allergy to a drug or drug class has been excluded by specialist investigation that they can now take this drug or drug class safely and ensure that their medical records are updated.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t3", "name": "documenting new suspected drug allergic reactions", "draggable": "true", "value": {"name": "documenting new suspected drug allergic reactions", "type": "treatment related", "time": "", "intention": "", "description": "title:documenting new suspected drug allergic reactionshead:Documenting new suspected drug allergic reactionsWhen a person presents with suspected drug allergy, document their reaction in a structured approach that includes: the generic and proprietary name of the drug or drugs suspected to have caused the reaction, including the strength and formulation  a description of the reaction (see assessment) the indication for the drug being taken (if there is no clinical diagnosis, describe the illness) date and time of the reaction the number of doses taken or number of days on the drug before onset of the reaction the route of administration  which drugs or drug classes to avoid in future.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.1Documentation using the structured assessment guide2Advice about carrying personal structured drug informationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t11", "name": "non specialist management and referral to specialist drug allergy services", "draggable": "true", "value": {"name": "non specialist management and referral to specialist drug allergy services", "type": "treatment related", "time": "", "intention": "", "description": "title:non-specialist management and referral to specialist drug allergy services", "drug": {}}}, {"category": "treatment", "id": "t18", "name": "testing and referral in under 19s", "draggable": "true", "value": {"name": "testing and referral in under 19s", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:testing and referral in under 19s", "drug": {}}}, {"category": "treatment", "id": "t4", "name": "maintaining and sharing drug allergy information", "draggable": "true", "value": {"name": "maintaining and sharing drug allergy information", "type": "treatment related", "time": "", "intention": "", "description": "title:maintaining and sharing drug allergy informationhead:Maintaining and sharing drug allergy informationPrescriptions (paper or electronic) issued in any healthcare setting should be standardised and redesigned to record information on which drugs or drug classes to avoid to reduce the risk of drug allergy.Ensure that drug allergy status is documented separately from adverse drug reactions and that it is clearly visible to all healthcare professionals who are prescribing drugs.Check a person s drug allergy status and confirm it with them (or their family members or carers as appropriate) before prescribing, dispensing or administering any drug (see also the recommendation on advising people to carry information they are given about their drug allergy in information and support). Update the person s medical records or inform their GP if there is a change in drug allergy status.Ensure that information about drug allergy status is updated and included in all: GP referral letters hospital discharge letters.Carry out medicines reconciliation for people admitted to hospital in line with NICE s recommendations on medicines optimisation.See also what NICE says on managing medicines in care homes.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.5Updating information on drug allergy status6Prescription information on drug avoidance: developmentalSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t5", "name": "documenting information after specialist drug allergy investigations", "draggable": "true", "value": {"name": "documenting information after specialist drug allergy investigations", "type": "treatment related", "time": "", "intention": "", "description": "title:documenting information after specialist drug allergy investigationshead:Documenting information after specialist drug allergy investigations After specialist drug allergy investigations, allergy specialists should document: the diagnosis, drug name and whether the person had an allergic or non-allergic reaction the investigations used to confirm or exclude the diagnosis drugs or drug classes to avoid in future.For recommendations on referral to specialist services see non-specialist management and referral to specialist drug allergy services.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG183", "drug": {}}}, {"category": "treatment", "id": "t6", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and support", "drug": {}}}]}